Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 7:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 7,390 matching trials from the live ClinicalTrials.gov search.
Conditions
Advanced Solid Tumors
Interventions
CP-868,596, Docetaxel, AG-013736
Drug
Lead sponsor
Arog Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Recruiting No phase listed Observational Accepts healthy volunteers

A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma

NCT03334708
Conditions
Pancreatic Cancer, Pancreatic Diseases, Pancreatitis, Pancreatic Cyst
Interventions
Blood Draw, Tumor Tissue Collection, Cyst Fluid
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
10
States / cities
Middletown, New Jersey • Montvale, New Jersey • Cold Spring Harbor, New York + 4 more
Conditions
Bladder Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma With Giant Cells, Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation, Infiltrating Bladder Urothelial Carcinoma With Trophoblastic Differentiation, Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant, Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant, Infiltrating Bladder Urothelial Carcinoma, Nested Variant, Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant
Interventions
Carboplatin, Cisplatin, Cystectomy, Doxorubicin, Durvalumab, Gemcitabine, Methotrexate, Vinblastine
Drug · Procedure · Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Solid Tumor, Hematological Malignancy
Interventions
Locus Health iPhone App
Device
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Fairfax, Virginia
Conditions
Advanced Solid Tumors
Interventions
VVD-159642, Sotorasib, Trametinib
Drug
Lead sponsor
Vividion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Grand Rapids, Michigan • Austin, Texas • Irving, Texas + 3 more
Conditions
Fabry Disease
Interventions
ST-920
Biological
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
9
States / cities
Irvine, California • Tampa, Florida • Atlanta, Georgia + 6 more
Conditions
Cancer, Metastasis, Metastatic Cancer, Brain Metastases, Brain Metastases, Adult
Interventions
Azeliragon, Stereotactic radiosurgery, Corticosteroid
Drug · Radiation
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Miami, Florida
Completed Phase 1 Interventional Accepts healthy volunteers

dMAbs for Prevention of COVID-19

NCT05293249
Conditions
Healthy Volunteers
Interventions
dMAb AZD5396, dMAb AZD8076, CELLECTRA™ 2000 with Side Port needle, OpBlock 0078 Electroporation device, Hylenex, CELLECTRA™ 2000 with Side Port needle, OpBlock 0070 Electroporation device
Combination Product · Drug
Lead sponsor
Pablo Tebas
Other
Eligibility
18 Years to 60 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Breast Cancer Related Lymphedema, Covid19
Interventions
Survey
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma
Interventions
tucatinib, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
21
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 10 more
Conditions
Hookworm Infection, Hookworm Disease
Interventions
10 μg Na-GST-1/Alhydrogel, 30 μg Na-GST-1/Alhydrogel, 100 μg Na-GST-1/Alhydrogel, 10 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg), 30 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg), 30 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg), 100 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Completed Not applicable Interventional

Endovascular Engineering ENGULF Study

NCT05597891
Conditions
Pulmonary Embolism
Interventions
Hēlo PE Thombectomy System
Device
Lead sponsor
Endovascular Engineering
Industry
Eligibility
18 Years to 90 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
21
States / cities
Los Angeles, California • Pasadena, California • Torrance, California + 13 more
Conditions
Healthy Volunteers
Interventions
INS1007, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 50 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Glendale, California
Conditions
Tumor, Solid
Interventions
Indocyanine Green
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma, T-cell Acute Lymphoblastic Leukemia
Interventions
Autologous CD5.CAR/28zeta CAR T cells, Allogeneic CD5.CAR/28zeta CAR T cells
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 75 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2040
U.S. locations
2
States / cities
Houston, Texas
Conditions
Solid Tumors
Interventions
nesvacumab (REGN910/ SAR307746), aflibercept (ziv-aflibercept)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Indianapolis, Indiana • New York, New York • Oklahoma City, Oklahoma + 2 more
Conditions
Beta-Thalassemia
Interventions
ACE-536
Drug
Lead sponsor
Celgene
Industry
Eligibility
6 Years to 17 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2035
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Conditions
Solid Tumors, Lymphoma
Interventions
Eflapegrastim, Chemotherapy
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
1 Month to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
Valhalla, New York • Charlotte, North Carolina • Cleveland, Ohio + 1 more
Conditions
Non Hodgkin's Lymphoma Refractory/Relapsed
Interventions
N803, CD19t-haNK suspension, Cyclophosphamide, Fludarabine, Rituximab
Drug · Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Newport Beach, California • Tyler, Texas
Conditions
Non-Small Cell Lung Cancer
Interventions
Durvalumab, Proton beam therapy RT
Drug · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Ewing Sarcoma
Interventions
LX-101
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
10 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2033
U.S. locations
1
States / cities
Houston, Texas
Conditions
Von Willebrand Disease
Interventions
Recombinant von Willebrand factor : recombinant FVIII (rVWF:rFVIII), Marketed plasma-derived VWF/FVIII concentrate
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Atlanta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 7 more
Conditions
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
CCI-779, Bevacizumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
2
States / cities
Rochester, Minnesota • Madison, Wisconsin
Conditions
Healthy
Interventions
REGN728
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
2
States / cities
Miramar, Florida • Overland Park, Kansas